STORM Therapeutics has announced the appointment of Marguerite Hutchinson as Chief Business Officer.
Marguerite has over ten years’ experience in leading licensing agreements and collaborations with large, high profile healthcare companies as well as experience in legal and strategic operations.
She was previously the Chief Operating Officer and General Counsel of Plexxikon – a member of the Daiichi Sankyo Group – establishing and managing collaborations with Roche, Merck, AstraZeneca, Array and Cancer Research UK.
She played a pivotal role in the out-licensing of bezuclastinib to Cogent Biosciences and plixorafenib to Fore Biotherapeutics. Marguerite was also instrumental in the phase 3 development and approval of pexidartinib, a prescription medicine that is the first and only oral therapy for tenosynovial giant cell tumour.
